MX2015008333A - Methods and compositions for administration of oxybutynin. - Google Patents

Methods and compositions for administration of oxybutynin.

Info

Publication number
MX2015008333A
MX2015008333A MX2015008333A MX2015008333A MX2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A MX 2015008333 A MX2015008333 A MX 2015008333A
Authority
MX
Mexico
Prior art keywords
salt
oxybutynin
agents
compositions
methods
Prior art date
Application number
MX2015008333A
Other languages
Spanish (es)
Inventor
Robert Cook
David A Byron
Scott Fleming
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/728,706 external-priority patent/US9119777B2/en
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of MX2015008333A publication Critical patent/MX2015008333A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to methods and compositions for treating pulmonary disease comprising delivering directly to a patient's lungs a therapeutically effective amount of oxybutynin in combination with one or more pharmaceutically effective agents. Oxybutynin may be selected from the group consisting of, but not limited to, a xinafoate salt, a palmitate salt, a pamoic salt, a resonate salt, a laurate salt and other salts. The pharmaceutically effective agents comprise bronchodilators, antiinflammatories, corticosteroids, corticosteroid reversal agent or alveolar growth agents or other agents selected from proteinase or protease inhibitors.
MX2015008333A 2012-12-27 2013-12-12 Methods and compositions for administration of oxybutynin. MX2015008333A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/728,706 US9119777B2 (en) 2008-05-30 2012-12-27 Methods and compositions for administration of oxybutynin
PCT/US2013/074759 WO2014105446A1 (en) 2012-12-27 2013-12-12 Methods and compositions for administration of oxybutynin

Publications (1)

Publication Number Publication Date
MX2015008333A true MX2015008333A (en) 2015-11-09

Family

ID=51021931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008333A MX2015008333A (en) 2012-12-27 2013-12-12 Methods and compositions for administration of oxybutynin.

Country Status (15)

Country Link
EP (1) EP2938329A4 (en)
JP (1) JP2016504358A (en)
KR (1) KR20150100902A (en)
CN (1) CN104955444A (en)
AR (1) AR094287A1 (en)
AU (1) AU2013368298B2 (en)
BR (1) BR112015015421A2 (en)
CA (1) CA2895955A1 (en)
EA (1) EA201591218A1 (en)
HK (2) HK1215396A1 (en)
IL (1) IL239623A0 (en)
MX (1) MX2015008333A (en)
NZ (1) NZ628479A (en)
UY (1) UY35230A (en)
WO (1) WO2014105446A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094626B1 (en) * 2016-02-25 2020-03-27 히사미쓰 세이야꾸 가부시키가이샤 Liquid for external use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071108A2 (en) * 1999-05-20 2000-11-30 Sepracor Inc. Methods for treatment of asthma using s-oxybutynin
US6339107B1 (en) * 2000-08-02 2002-01-15 Syntex (U.S.A.) Llc Methods for treatment of Emphysema using 13-cis retinoic acid
CA2498189A1 (en) * 2002-10-29 2004-05-13 Pharmacia & Upjohn Company Llc Quaternary ammonium compounds
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US20060110449A1 (en) * 2004-10-25 2006-05-25 Lorber Richard R Pharmaceutical composition
US8415390B2 (en) * 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
AU2009241628A1 (en) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
JP2012530134A (en) * 2009-06-16 2012-11-29 タン，ウェン Use of R-type bambuterol as a combination therapy and inhalation drug in the treatment of respiratory diseases
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
KR101730684B1 (en) * 2010-04-01 2017-04-26 키에시 파르마슈티시 엣스. 피. 에이. Process for preparing carrier particles for dry powders for inhalation
CA2812952A1 (en) * 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation

Also Published As

Publication number Publication date
AU2013368298B2 (en) 2016-08-11
NZ628479A (en) 2016-06-24
HK1216843A1 (en) 2016-12-09
EP2938329A4 (en) 2016-08-10
AU2013368298A1 (en) 2015-07-02
HK1215396A1 (en) 2016-08-26
AR094287A1 (en) 2015-07-22
UY35230A (en) 2015-01-30
WO2014105446A1 (en) 2014-07-03
EP2938329A1 (en) 2015-11-04
IL239623A0 (en) 2015-08-31
KR20150100902A (en) 2015-09-02
CN104955444A (en) 2015-09-30
JP2016504358A (en) 2016-02-12
EA201591218A1 (en) 2015-11-30
CA2895955A1 (en) 2014-07-03
BR112015015421A2 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
UA115139C2 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
RU2012140704A (en) METHOD FOR PREVENTION AND / OR TREATMENT OF FIBROSIS AND / OR REMOVAL OF THE CORNETAL (OPTIONS), METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR PREVENTION AND / OR TREATMENT OF FIBROSIS AND / OR REMOVAL PRACTICE
PH12015501108B1 (en) Treatment of pulmonary disease
JP2013520405A5 (en)
WO2014099226A3 (en) Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
UA113165C2 (en) APPLICATION OF A COMBINATION OF Baclofen AND ACOMPROSAT FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND A COMPOSITION CONTAINING Baclofen AND ACAMPROSAT
HK1167641A1 (en) 4-hydroxybutyric acid analogs 4-
BR112013029246A2 (en) 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazol-2-yl] -1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
NZ609719A (en) Pharmaceutical composition
MX2012005013A (en) Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures.
WO2011139794A3 (en) A composition for skin sanitization and protection and method of its use
WO2009099998A3 (en) Therapeutic treatment for lung conditions
BR112014010729A2 (en) methods for treating gout attacks
MX2015008187A (en) Deuterated alk inhibitors.
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
MX350195B (en) Cystamine analogues for the treatment of parkinson's disease.
MX336278B (en) Compositions and methods for prevention and treatment of wounds.
NZ629964A (en) Method for treating inflammation
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases